sponsored
PatientsVille.com Logo

PatientsVille

Andrews Medical Research Studies

Up-to-date List of Andrews Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Andrews Medical Research Studies

Rank Status Study
1 Not yet recruiting Clinician-patient Interaction During Addiction Consultation
Condition: Drug Dependency
Intervention: Other: methadone replacement therapy
Outcome Measures: Number of days patients injected non-prescribed drugs;   Patient Satisfaction
2 Unknown  Personalizing Health Outcome in Epilepsy Now - An Introduction to Clinical Services
Condition: Medically Intractable Epilepsy
Interventions: Behavioral: Andrews/Reiter approach to epilepsy;   Behavioral: Relaxation/Meditation
Outcome Measures: Fraction of seizure free study subjects;   Fraction of subjects achieving a clinically meaningful reduction of seizure frequency;   Subjective Handicap of Epilepsy;   Health-related self-efficacy;   Psychopathologic disorders and stress;   Quality of life
3 Recruiting Donor Lymphocyte Infusion After Alternative Donor Transplantation
Condition: Immunocompromised After T-cell Depleted Transplant.
Intervention: Biological: Infusion of donor lymphocytes
Outcome Measures: Immune recovery following transplantation;   Incidence and severity of GVHD;   Determine incidence of infection and EBV-related post-transplant lymphoproliferative disease (PTLD)
4 Recruiting Window of Opportunity Trial of ADXS 11-001 Vaccination Prior to Robotic Surgery of HPV-Positive Oropharyngeal Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma
Intervention: Biological: ADXS11-001 (ADXS-HPV)
Outcome Measures: change in HPV E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses;   Toxicity;   Vaccine induced HPV E6/E7specific CD8+ CTL responses
5 Recruiting Belatacept Therapy for the Failing Renal Allograft
Condition: Renal Transplant
Interventions: Drug: belatacept (Nulojix);   Drug: Calcineurin inhibitor therapy;   Drug: mycophenolate mofetil;   Drug: prednisone
Outcome Measures: Development of donor-specific antibody;   preservation of glomerular filtration rate
6 Recruiting Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination
Condition: Multiple Sclerosis
Interventions: Drug: Dexrazoxane and Mitoxantrone;   Drug: Mitoxantrone (MX)
Outcome Measures: Changes in LVEF in the different treatment arms by cardiac MRI;   Changes in LVEF by transthoracic echocardiography and determination of cardiac side effects by ECG and by measurement of CK-MB, Troponin and BNP in mitoxantrone plus dexrazoxane versus mitoxantrone plus placebo treatment arms;   Determination of EDSS and relapse rate in mitoxantrone plus dexrazoxane treatment arm versus mitoxantrone plus placebo treatment arm;   Cumulative number of active lesions by cMRI;   LVEF in 3D-echocardiography vs. LVEF in cardiac MRI;   Clinical efficacy of DRZ+MX vs. MX monotherapy by MSFC;   Quality of Life by SF-36 questionnaire;   Changes in magnetic evoked potentials: prolongation of TMCT+CMCT, potential configuration;   Annual brain atrophy rates in cMRI;   Changes in transcranial sonography (abnormal iron deposition AID). AID in cMRI. Comparison of both methods;   Analysis of ABD transporter gene polymorphisms as predictor of therapy response and side effect profile via TaqMan PCR
7 Recruiting Randomized Controlled Trial of Argatroban With tPA for Acute Stroke
Condition: Ischemic Stroke
Intervention: Drug: Argatroban
Outcome Measures: Percentage of patients with 0 or 1 on Modified Rankin Scale;   Incidence of hemorrhage;   Rates of recanalization;   Improvement in neurological deficits;   Cost effectiveness
8 Recruiting Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
Conditions: Hematologic Neoplasms;   Anemia, Aplastic;   Hemoglobinuria, Paroxysmal;   Multiple Myeloma
Intervention: Other: haploidentical allogeneic PBSC transplant
Outcome Measures: The primary efficacy endpoint is the presence of donor lymphohematopoietic chimerism (defined as at least 50% donor cells in the peripheral blood)in peripheral blood by day +100.;   To determine the safety of haploidentical related allogeneic PBSCT using a preparative regimen of busulfan, melphalan and alemtuzumab.
9 Recruiting T-cell Depleted Alternative Donor Transplantation
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis
Intervention: Device: CliniMACS® (T cell depletion)
Outcome Measures: Determine rate of severe GVHD.;   Evaluate the rate of engraftment;   Evaluate post-transplant infections;   Evaluate rate of EBV-related post transplant lymphoproliferative disorder (PTLD);   Evaluate post-transplant leukemia relapse;   Evaluate transplant-related mortality;   Evaluate transplant-related toxicities;   Evaluate overall survival;   Monitor device performance: purity of selected product, yield of CD34+ cells, CD3+ cell depletion, viability and sterility.
10 Recruiting Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Conditions: Pigmented Villonodular Synovitis;   Diffuse-type Giant Cell Tumor;   Tenosynovial Giant Cell Tumor
Intervention: Drug: nilotinib
Outcome Measures: Progression free survival;   Overall tumor response rate;   Clinical Benefit Rate
11 Recruiting The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: tasquinimod;   Drug: tasquinimod 0.25 mg; 0.5 mg;   Drug: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Outcome Measures: The primary objective is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).;   Evaluation of progression free survival;   Preliminary evidence of efficacy will be determined by several criteria, one of which is PSA declines;   Preliminary evidence of efficacy will be determined by several criteria, one of which is circulating tumor cell changes over time;   Measurement of the rates of radiographic response along with duration of responses.
12 Unknown  Single Centre Study to Compare Harmonic Scalpel to Conventional Diathermy in Free Tissue Transfer Breast Reconstruction
Condition: Breast Reconstruction
Interventions: Procedure: Harmonic Synergy Dissecting Hook (Harmonic Scalpel);   Procedure: Electrocautery Diathermy
Outcome Measures: The speed of flap harvest measured as the time from "knife to skin" to the flap being removed from the patient.;   Ease of flap harvest: the subjective opinion of the surgeon based on structured questionnaire;   Post operative pain, based on the visual analogue scale at 3, 6, 12 and 24 weeks post operatively.;   Rates of post operative infection;   Incidence of abdominal (donor site) wound dehiscence;   Bleeding complications;   Return to theatre;   Incidence of seroma;   Post operative drainage from the wound;   Impact on daily activities (SF-36 Questionnaire) at 3, 6, 12 and 24 weeks post operatively;   Number of days of hospitalisation;   Re-operation required
13 Unknown  PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers
Conditions: Middle Ear Effusion;   Tympanic Membrane Perforation;   Acute Otitis Media;   Pneumococcal Infections
Intervention: Biological: 23vPPV, dTpa (Pneumovax, Boostrix)
Outcome Measures: Prevalence of middle ear disease, defined as middle ear effusion or tympanic membrane perforation or acute otitis media;   Nasopharyngeal carriage of vaccine type pneumococci;   Prevalence of middle ear disease;   Relationship of maternal pneumococcal carriage, maternal anti-pneumococcal antibody levels, cord blood antibody levels and breast milk antibody levels to infant carriage and middle ear disease;   Impact of each maternal vaccination strategy on breast milk antibody levels to serotypes contained in the vaccine;   Impact of each maternal vaccination strategy on breast milk antibody avidity (to four selected serotypes);   Impact of each maternal vaccination strategy on maternal antibody response to antepartum or postpartum 23vPPV;   Impact of each maternal vaccination strategy on infant anti-pneumococcal antibody levels (following the 3rd recommended dose of 7vPCV)
14 Recruiting Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL)
Condition: Giant Cell Arteritis
Interventions: Procedure: Ultrasound of temporal and axillary arteries;   Procedure: Temporal artery biopsy
Outcome Measures: To evaluate the diagnostic accuracy (sensitivity and specificity) of ultrasound as an alternative to temporal artery biopsy for the diagnosis of GCA in patients referred for biopsy with suspected GCA.;   To evaluate the cost-effectiveness (incremental cost per QALY) of ultrasound instead of biopsy in the diagnosis of GCA.;   To evaluate inter-observer agreement in the assessment of ultrasound and temporal artery biopsy;   To elicit expert views on the appropriateness of performing a biopsy following ultrasound using clinical vignettes;   To evaluate the diagnostic accuracy (sensitivity and specificity) of the sequential diagnostic strategy as an alternative to temporal artery biopsy alone in the diagnosis of GCA;   To evaluate the cost-effectiveness (incremental cost per QALY) of the diagnostic strategy of combined ultrasound and biopsy instead of biopsy alone in the diagnosis of GCA.;   Specific adverse events measured at each assessment; daily and cumulative steroid dose; steroid side effects; and pain or dysaesthesia at the biopsy site.;   Evolution of an alternative diagnosis;   Negative predictive value of ultrasound in preventing the need for temporal artery biopsies.;   Cost analysis of performing a screening ultrasound examination plus biopsy as part of the diagnostic workup of all patients with suspected GCA; or of performing a screening ultrasound examination instead of biopsy; or of performing a screening ultrasound;   Cost analysis of performing a screening ultrasound examination instead of biopsy in cases with a very low probability of GCA as part of the diagnostic workup of all patients with suspected GCA.;   Prediction of potential harm done to patients by over diagnosis or under diagnosis of GCA as a result of ultrasound use, either alone or in combination with biopsy;   Value of axillary artery ultrasound scanning in contributing to the diagnosis of GCA.;   Analysis of proportion of patients with a biopsy positive halo, stenosis, or occlusion assessed by high resolution ultrasound;   Presence of characteristic features of GCA on temporal artery biopsy in relation to clinical and ultrasound findings
15 Recruiting SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)
Condition: Prostate Cancer
Intervention: Radiation: Stereotactic ablative radiotherapy
Outcome Measures: Acute GU and GI toxicities;   Late GU and GI toxicities;   Quality of Life (QoL);   Biochemical control;   Disease free survival
16 Unknown  A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease
Condition: HIV Infections
Intervention: Drug: etanercept
Outcome Measures: changes in CD4 counts;   changes in HIV-RNA levels;   development of infections;   degree of TNF inhibition by measuring TNF levels;   changes in hematologic and biochemical laboratory tests
17 Unknown  Closed-Loop Insulin Delivery in Children Less Than 7 Years of Age
Condition: Type 1 Diabetes Mellitus
Interventions: Procedure: Closed-loop therapy;   Procedure: Standard Insulin Pump Therapy
Outcome Measures: Nocturnal Glycemic Control;   Post-prandial glycemic control;   Nocturnal hypoglycemia and hyperglycemia;   Continuous glucose monitor accuracy;   Daytime hypoglycemia and hyperglycemia
18 Recruiting Management of Occult Pneumothoraces in Mechanically Ventilated Patients
Condition: Pneumothorax
Interventions: Procedure: chest drainage;   Other: close clinical observation
Outcome Measures: Outcome Variables: In ventilated patients with small to moderate sized occult PTXs, the rate of respiratory distress will not differ between those treated with chest thoracostomy tubes and those not treated but simply observed;   Observation of small OPTXs in ventilated patients will not increases the rates of Emergency chest drainage, Death, tracheostomy, ARDS, Ventilator associated pneumonia (VAP), or the Abdominal Compartment Syndrome (ACS)
19 Recruiting Sepsis and Abdominal Drainage
Conditions: Abdominal Compartment Syndrome;   Intra-abdominal Hypertension
Interventions: Device: KCI AbThera;   Device: "Stampede" VAC
Outcome Measures: Systemic inflammatory marker levels and peritoneal fluid inflammatory marker levels;   Physiological Outcomes;   Global Outcomes
20 Recruiting Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer
Condition: Prostate Cancer
Intervention: Radiation: Hypofractionated radiation
Outcome Measures: Incidence of grade 3+ rectal toxicity;   Incidence of grade 3+ urinary toxicity;   Quality of Life;   Biochemical (ie.prostate specific antigen) disease free survival

These studies may lead to new treatments and are adding insight into Andrews etiology and treatment.

A major focus of Andrews research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Andrews